Friday, November 18, 2022 (Black Bear Room)

2:00-2:10 Welcome (John Lewis, PhD.)-
Tribute Stewart Campbell and Arni Goodman.
2:10-2:40 Introduction (John Lewis, PhD.)
2:40-3:00 New APCaRI initiatives - the next 5 years (Adam Kinnaird, MD., PhD.)

Biomarkers, Metastasis and Clinical Cohorts

3:00-3:50 KEYNOTE: "But what if....? Treatment regret in localized prostate cancer" Christopher Wallis, Assistant Professor, University of Toronto and Urologic Oncologist, Mount Sinai Hospital and University Health Network.
3:50-4:10 "Proteinase Signaling, Inflammatory Disease and Cancer", M.D. Hollenberg, D. Phil, MD, Professor, Departments of Physiology & Pharmacology, University of Calgary Cumming School of Medicine.
4:10-4:40 Janssen Break
4:40-5:00 “Economic Evaluation of Testing for Prostate Cancer Diagnosis in Alberta: PSA, Clarity DX®, and mpMRI”, Charles Yan, Senior Principal Economist.
5:00-5:15 “PSA testing rates in indigenous vs. non-indigenous communities in Alberta” Alex Kiciak, MD.
5:15-5:30 “ClarityDx Bladder - Development Program”, Argo Basu, PhD.

Imaging

5:30-5:50 “Advances in Ultrasound-Aided Biomarker Release and Virtual Histology for Prostate Cancer”, Roger Zemp, PhD.
5:50-6:05 “Intravital imaging reveals complementary Wnt/b-catenin and Wnt/ATF2-dependent signaling activities during human tumour cell invasion and metastasis”, Konstantin Stoletov, PhD.
6:05-6:20 “The Next Generation Trial – The first six months: Assessing 18F-PSMA-1007 positron emission tomography and magnetic resonance imaging in the primary staging of prostate cancer patients”, Nikhile Mookerji, MD.

6:30-11:00 Merck & AstraZeneca Dinner - Networking - Cash bar (Black Bear Room)

Saturday, November 19, 2022 (Black Bear Room)

7:00-8:30 Pfizer Breakfast Buffet (Carve Mountain Grill)
8:30-8:50 Updates on Alberta PCa Cohorts: Registry & Biorepository, Anais Medina Martin, PhD
8:50-9:10 Future of Genetic Testing in Prostate Cancer within Alberta, Steve Yip, MD, MSc.

Proteomics, Genomics, and Prostate Cancer

Generously supported by:
Program
APCaRI Fall Symposium 2022
Nov. 18-19 2022, Banff Park Lodge

9:10-10:00  KEYNOTE: "The evolution of lethal prostate cancer" Paul Boutros, PhD., Data Scientist and Professor in the Departments of Human Genetics and Urology at the David Geffen School of Medicine at UCLA.

10:00-10:30  Merck Break

10:30-10:50  “Update of Proposed Molecular Platforms in Prostate Cancer Patients in Alberta”, Tarek Bismar, PhD., Professor and Deputy Head, Dept of Pathology and Lab Medicine U Calgary Cumming School of Medicine

10-50-11:10  “Discovery of Proteomic and Proteogenomic Biomarkers of Prostate Cancer” Andrei P. Drabovich, PhD.

10-50-11:25  “Role of Zyxin in Gene Regulation and Cell Proliferation”, M. Quadir Siddiqui, PhD.

11:25-11:40  “Clinical-Grade Comprehensive Genomic Profiling of Advanced/Metastatic Prostate and Bladder cancers”, Pinaki Bose, PhD. Scientific Lead, Precision Oncology and Experimental Therapeutics (POET), Charbonneau Cancer Institute, University of Calgary, Co-Founder, VP Planning and Management, OncoHelix Inc.

11:40-11:55  “ARPC1B overexpression Is Significantly Associated with ERG/PTEN in Lethal Prostate Cancer and Its Inhibition Decreases Cell Invasion and Migration In Vitro”, Yaser Gamallat, PhD.

11:55-1:30  Bayer & Astellas Lunch & Team picture (Black Bear Room)

Artificial Intelligence and Machine Learning

1:30-2:20  KEYNOTE: “How better software engineering improves scientific and medical research.” Vijay Pandurangan, Prof. MSc., Adjunct Professor at Stanford School of Medicine.

2:20-2:40  Ross Mitchell. TBD

2:40-2:55  “Learning to Predict Prostate Cancer Recurrence from Tissue Images”, Mahtab Farrokh, MSc.

2:55-3:10  "Evolution of the ClarityDX Prostate test: Optimizing test accuracy and costs”, Robert Paproski, PhD.

3:10-3:25  AstraZeneca Break

Cancer Therapy & Imaging

3:25-3:45  “Outcomes of first subsequent taxane (FST) therapy in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) who received docetaxel intensification (DI) in metastatic castration-sensitive prostate cancer (mCSPC) as treated at the Cross Cancer Institute (CCI).” Gabrielle Robin, MD.

3:45-4:00  “The Alberta LINAC-MR P3 system”, Arun Elangovan, MD.

4:00-4:15  Discussion, closing remarks, and adjournment

Executive and Science & Data Quality Committee meeting (Black Bear Room)

4:30-6:00  Executive Committee and Science and Data Quality Committee meeting

6:00-8:00  Janssen Dinner for Executive Committee (La Terraza)

Generously supported by: